[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX339867B - Forma de dosificacion oral de liberacion prolongada de acetaminofeno/tramadol. - Google Patents

Forma de dosificacion oral de liberacion prolongada de acetaminofeno/tramadol.

Info

Publication number
MX339867B
MX339867B MX2011004403A MX2011004403A MX339867B MX 339867 B MX339867 B MX 339867B MX 2011004403 A MX2011004403 A MX 2011004403A MX 2011004403 A MX2011004403 A MX 2011004403A MX 339867 B MX339867 B MX 339867B
Authority
MX
Mexico
Prior art keywords
tramadol
dosage form
acetaminophen
extended release
release oral
Prior art date
Application number
MX2011004403A
Other languages
English (en)
Other versions
MX2011004403A (es
Inventor
Wei-Guo Dai
Liang-Chang Dong
Tae-Hong Choi
Sung Joo Hwang
Jae Hyun Kim
Dong Ho Lee
Original Assignee
Alza Corp *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41514164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX339867(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alza Corp * filed Critical Alza Corp *
Publication of MX2011004403A publication Critical patent/MX2011004403A/es
Publication of MX339867B publication Critical patent/MX339867B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una forma de dosificación de liberación prolongada de administración oral de acetaminofeno y tramadol. La forma de dosificación incluye una composición de acetaminofeno junto con un complejo de tramadol formado con un polímero aniónico. El complejo de tramadol proporciona la liberación sostenida de tramadol para un perfil de liberación sincronizado (coordinado) de acetaminofeno y tramadol.
MX2011004403A 2008-10-27 2009-10-23 Forma de dosificacion oral de liberacion prolongada de acetaminofeno/tramadol. MX339867B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10861808P 2008-10-27 2008-10-27
PCT/US2009/061803 WO2010062524A1 (en) 2008-10-27 2009-10-23 Extended release oral acetaminophen/tramadol dosage form

Publications (2)

Publication Number Publication Date
MX2011004403A MX2011004403A (es) 2011-05-25
MX339867B true MX339867B (es) 2016-06-14

Family

ID=41514164

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011004403A MX339867B (es) 2008-10-27 2009-10-23 Forma de dosificacion oral de liberacion prolongada de acetaminofeno/tramadol.

Country Status (26)

Country Link
US (1) US20100104638A1 (es)
EP (1) EP2362768B1 (es)
JP (1) JP5713911B2 (es)
KR (3) KR20110036858A (es)
CN (2) CN102264355A (es)
AU (1) AU2009320181B2 (es)
BR (1) BRPI0920082A2 (es)
CA (1) CA2741751C (es)
CL (1) CL2011000935A1 (es)
CO (1) CO6331423A2 (es)
CR (1) CR20110287A (es)
EA (1) EA023149B1 (es)
EC (1) ECSP11011009A (es)
ES (1) ES2582779T3 (es)
HK (1) HK1162915A1 (es)
HN (1) HN2011001184A (es)
IL (1) IL212453A (es)
MX (1) MX339867B (es)
MY (1) MY161550A (es)
NI (1) NI201100079A (es)
NZ (1) NZ592325A (es)
PE (1) PE20110855A1 (es)
TW (1) TWI561257B (es)
UA (1) UA102706C2 (es)
WO (1) WO2010062524A1 (es)
ZA (1) ZA201103880B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10361596A1 (de) * 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
BRPI0906467C1 (pt) 2008-01-25 2021-05-25 Gruenenthal Gmbh forma de dosagem farmacêutica com formato exterior modificado resistente à ruptura e com liberação controlada
JP5674641B2 (ja) 2008-05-09 2015-02-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 噴霧凝固工程の適用下での中間粉末製剤および最終固体剤形の製造方法
PL2456424T3 (pl) * 2009-07-22 2013-12-31 Gruenenthal Gmbh Stabilizowana przed utlenianiem odporna na naruszenie postać dawkowania
CA2765971C (en) 2009-07-22 2017-08-22 Gruenenthal Gmbh Hot-melt extruded controlled release dosage form
PE20131126A1 (es) 2010-09-02 2013-10-21 Gruenenthal Chemie Forma de dosificacion resistente a alteracion que comprende un polimero anionico
NZ607392A (en) 2010-09-02 2015-03-27 Gruenenthal Chemie Tamper resistant dosage form comprising inorganic salt
EP2704697B1 (en) * 2011-05-06 2018-09-12 GlaxoSmithKline Consumer Healthcare (UK) IP Limited Sustained release paracetamol formulations
US10702485B2 (en) * 2011-07-09 2020-07-07 Syntrix Biosystems Inc. Compositions and methods for overcoming resistance to tramadol
SI2736495T1 (sl) 2011-07-29 2017-12-29 Gruenenthal Gmbh Tableta, odporna proti zlorabi, ki zagotavlja takojšnje sproščanje zdravila
NO2736497T3 (es) 2011-07-29 2018-01-20
EP2819656A1 (en) 2012-02-28 2015-01-07 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
MX362357B (es) 2012-04-18 2019-01-14 Gruenenthal Gmbh Forma de dosificacion farmaceutica resistente a la adulteracion y resistente a la liberacion inmediata de la dosis.
EP2846812A2 (en) * 2012-05-10 2015-03-18 FMC Corporation Controlled release solid dose form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
MX371432B (es) 2013-05-29 2020-01-30 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido que contiene una o mas particulas.
DE102013009114A1 (de) 2013-05-29 2014-12-04 Franz Gerstheimer Pharmazeutische Zusammensetzung zur Überwindung von Metabolisierungsproblemen
MX2015016254A (es) 2013-05-29 2016-04-20 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal.
EP3019157A1 (en) 2013-07-12 2016-05-18 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
IN2013MU03098A (es) * 2013-09-30 2015-07-17 Athena Drug Delivery Solutions Pvt Ltd
CA2931553C (en) 2013-11-26 2022-01-18 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling
CN105764491A (zh) 2013-12-09 2016-07-13 度瑞公司 药物活性剂复合物、聚合物复合物，以及包括其的组合物和方法
US20150164807A1 (en) * 2013-12-16 2015-06-18 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile manufactured by co-extrusion
CA2947786A1 (en) 2014-05-12 2015-11-19 Grunenthal Gmbh Tamper resistant immediate release capsule formulation comprising tapentadol
CA2949422A1 (en) 2014-05-26 2015-12-03 Grunenthal Gmbh Multiparticles safeguarded against ethanolic dose-dumping
CA2983642A1 (en) 2015-04-24 2016-10-27 Grunenthal Gmbh Tamper-resistant dosage form with immediate release and resistance against solvent extraction
CA2998259A1 (en) 2015-09-10 2017-03-16 Grunenthal Gmbh Protecting oral overdose with abuse deterrent immediate release formulations
EP3694557B1 (en) * 2017-10-13 2022-04-13 Altus Formulation Inc. Starch-based release modifying excipients and pharmaceutical compositions derived therefrom
GB2567493B (en) 2017-10-13 2019-12-18 Altus Formulation Inc Starch-based release modifying excipients and pharmaceutical compositions derived therefrom
US11000488B2 (en) 2019-03-22 2021-05-11 Syntrix Biosystems Inc. Treating pain using desmetramadol
KR20240027436A (ko) * 2022-08-23 2024-03-04 대원제약주식회사 펠루비프로펜 및 트라마돌의 이온결합 화합물, 이를 포함하는 조성물, 및 이의 제조 방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58206751A (ja) * 1982-05-26 1983-12-02 日石三菱株式会社 創傷被覆材
HU219332B (hu) 1991-09-06 2001-03-28 Mcneilab Inc Transz-(+)-2-[(dimetil-amino)-metil]-1-(3-metoxi-fenil)-ciklohexanolt és acetaminofent tartalmazó szinergetikus gyógyszerkészítmények
CA2173818A1 (fr) * 1996-04-10 1997-10-11 Francois Chouinard Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose
US6375957B1 (en) * 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
AU2003271024A1 (en) 2002-09-21 2004-04-08 Jin Wang Sustained release compound of acetamidophenol and tramadol
CA2503155A1 (en) * 2002-10-25 2004-05-06 Labopharm Inc. Sustained-release tramadol formulations with 24-hour efficacy
WO2006053012A2 (en) * 2004-11-10 2006-05-18 Trinity Laboratories, Inc. Novel pharmaceutical compositions for treating acquired chronic pain and associated dysphoria
JP5371427B2 (ja) * 2005-07-07 2013-12-18 ファーナム・カンパニーズ・インコーポレーテッド 高水溶性薬剤用徐放性医薬組成物
KR101655455B1 (ko) * 2005-09-09 2016-09-07 안젤리니 라보팜 엘엘씨 일일 1회 투여를 위한 트라조돈 조성물
CN1785167A (zh) * 2005-10-08 2006-06-14 王鸣 一种非麻醉性镇痛剂的复方缓释制剂的制备方法
DE102006056458A1 (de) * 2006-11-28 2008-05-29 Grünenthal GmbH Arzneimittelzubereitung von Tramadol und Acetaminophen
JP5539868B2 (ja) * 2007-07-18 2014-07-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｔｒｐｍ８モジュレーターとしてのスルホンアミド類
WO2009076764A1 (en) * 2007-12-17 2009-06-25 Labopharm Inc. Misuse preventative, controlled release formulation
CA2720108C (en) * 2008-03-11 2016-06-07 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic

Also Published As

Publication number Publication date
CA2741751A1 (en) 2010-06-03
HK1162915A1 (zh) 2012-09-07
MX2011004403A (es) 2011-05-25
US20100104638A1 (en) 2010-04-29
NZ592325A (en) 2012-09-28
WO2010062524A1 (en) 2010-06-03
CA2741751C (en) 2017-05-09
ES2582779T3 (es) 2016-09-15
JP2012506907A (ja) 2012-03-22
EP2362768A1 (en) 2011-09-07
KR20110036858A (ko) 2011-04-11
AU2009320181B2 (en) 2015-08-27
CN102264355A (zh) 2011-11-30
AU2009320181A1 (en) 2010-06-03
EA201170616A1 (ru) 2011-12-30
CL2011000935A1 (es) 2011-10-21
JP5713911B2 (ja) 2015-05-07
EA023149B1 (ru) 2016-04-29
EP2362768B1 (en) 2016-04-20
CN107028908A (zh) 2017-08-11
KR20110119845A (ko) 2011-11-02
BRPI0920082A2 (pt) 2019-09-24
MY161550A (en) 2017-04-28
PE20110855A1 (es) 2011-12-05
ECSP11011009A (es) 2011-06-30
KR101631140B1 (ko) 2016-06-20
IL212453A0 (en) 2011-06-30
CR20110287A (es) 2011-11-10
CO6331423A2 (es) 2011-10-20
UA102706C2 (ru) 2013-08-12
HN2011001184A (es) 2014-09-01
IL212453A (en) 2017-03-30
TW201028180A (en) 2010-08-01
NI201100079A (es) 2011-10-21
TWI561257B (en) 2016-12-11
KR20130137720A (ko) 2013-12-17
ZA201103880B (en) 2012-10-31

Similar Documents

Publication Publication Date Title
MY161550A (en) Extended release oral acetaminophen/tramadol dosage form
AR114143A2 (es) Formulaciones de comprimidos revestidos
MX2009006235A (es) Composiciones farmaceuticas y sus metodos de uso.
MX2013005974A (es) Formulacion de lacosamida de administracion una vez al dia.
SG158799A1 (en) New process for the preparation of functionalised benzocyclobutenes, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
HK1148202A1 (en) Pharmaceutical solutions, process of preparation and therapeutic uses
TN2012000195A1 (en) Solid dispersion of rifaximin
NZ598127A (en) Cancer metastasis inhibitor
SG171542A1 (en) Pharmaceutical composition comprising a strontium salt, vitamin d and a cyclodextrin
SG162671A1 (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
PL2217219T3 (pl) Podjęzykowa musująca tabletka progesteronu w połączeniu z cyklodekstryną
MY146245A (en) New process for the synthesis of 7,8-dimethoxy-1,3-dihydro-2h-3-benzazepin-2-one, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
MY191875A (en) Solid dosage form
MX2012011382A (es) Nuevo polimero.
MX2013012918A (es) Formulaciones de liberacion sostenida de paracetamol.
MX349563B (es) Formulacion farmaceutica de fenofibrato nanonizado.
WO2010079433A3 (en) Pharmaceutical composition comprising melogliptin
AR067351A1 (es) Combinacion de picotamida con nafronil
EA200901387A1 (ru) Фармацевтическая композиция, включающая дезлоратадин
TR201109159A2 (tr) Eplerenon içeren film kaplı tablet kompozisyonu.
CR20130288A (es) Comprimido farmacéutico de liberación controlada para administración oral
TN2010000243A1 (en) Pharmaceutical composition
UA27344U (en) Use of pollentar pharmaceutical composition as cerebroprotective agent
UA36724U (ru) Состав сухой микстуры от кашля
JO2568B1 (en) New pharmaceutical excipients Ketosan for use in solid dosage forms

Legal Events

Date Code Title Description
FG Grant or registration